Results 161 to 170 of about 291,386 (352)

Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis

open access: yesClinical Genetics, EarlyView.
CFTR carrier status detected via prenatal screening is associated with increased pancreatitis risk in women, but clinical recognition remains low. Integrating carrier results into electronic health records may enhance personalized care and aid in early diagnosis. ABSTRACT This study assessed the effect of CFTR pathogenic variant status, detected during
Lucas D. Richter   +3 more
wiley   +1 more source

Evaluation of Continuous Antibiotic Therapy in Chronic Bronchitis [PDF]

open access: green, 1959
J. McC. Murdoch   +4 more
openalex   +1 more source

Acute Laryngo-tracheo-bronchitis [PDF]

open access: green, 1959
A. M. Peach, Elisabeth Zaiman
openalex   +1 more source

Association of allergen stability and epithelial barrier function in sensitized patients

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Panallergen families differ in their stability to heat and pH, which affects both the severity and clinical manifestations of allergic reactions. The extent of epithelial barrier dysfunction is thought to influence sensitization to different allergens.
Hannes Nösslinger   +5 more
wiley   +1 more source

Blood group O expression in normal tissues and tumors

open access: yesThe FEBS Journal, EarlyView.
The H antigen (O blood group), the precursor to A and B blood groups, is expressed on human erythrocytes. Two novel monoclonal antibodies generated using sea lamprey immunization, Tn4‐31L and OmcFL3‐02, specifically detect the H antigen on glycan microarrays, glycoproteins, and human cells.
Ea Kristine Clarisse Tulin   +11 more
wiley   +1 more source

Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors

open access: yesHaemophilia, EarlyView.
Introduction Eptacog beta is an activated recombinant human factor VII bypassing agent approved for treating bleeding episodes (BEs) in patients aged ≥12 years with haemophilia A or B with inhibitors. Two initial dose regimens (IDRs) of either 75 or 225 µg/kg, followed by 75 µg/kg, are approved.
Manuel Carcao   +7 more
wiley   +1 more source

Combined screening of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in an emergency department: The URDEPTRIO cross‐sectional study

open access: yes
Academic Emergency Medicine, EarlyView.
Chris Wong   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy